WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with high incidences of p53 mutations. AZD1775 (adavosertib, previously MK-1775) is a small molecule WEE1 inhibitor that abrogates the G2M checkpoint and can potentially synergize with DNA damaging therapies commonly used in PDAC trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartman, Sarah J., Bagby, Stacey M., Yacob, Betelehem W., Simmons, Dennis M., MacBeth, Morgan, Lieu, Christopher H., Davis, S. Lindsey, Leal, Alexis D., Tentler, John J., Diamond, Jennifer R., Eckhardt, S. Gail, Messersmith, Wells A., Pitts, Todd M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044903/
https://www.ncbi.nlm.nih.gov/pubmed/33869031
http://dx.doi.org/10.3389/fonc.2021.642328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044903/
https://www.ncbi.nlm.nih.gov/pubmed/33869031
http://dx.doi.org/10.3389/fonc.2021.642328

Ejemplares similares